The Hill, August 13, 2014
Regulators need to provide a clearer direction for the 22-year-old federal program that provides drug discounts to safety net hospitals, researchers argued in a new paper. The RAND Corp. said the so-called 340B program faces uncertainty when it comes to eligibility and transparency that pose challenges to healthcare providers and drug companies. "Policymakers need a clear, objective description of the 340B program and the challenges it faces on the road ahead," said Andrew Mulcahy, the report's lead author, in a statement. "There are increasingly divergent views on the program's purpose and the role it should play in supporting safety net providers."